Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND Resistant hypertension is associated with increased cardiovascular risk. The endothelin pathway has been implicated in the pathogenesis of hypertension, but it is currently not targeted therapeutically, thereby leaving this relevant pathophysiological pathway unopposed with currently available drugs. The aim of the study was to assess the blood pressure lowering efficacy of the dual endothelin antagonist aprocitentan in patients with resistant hypertension. METHODS PRECISION was a multicentre, blinded, randomised, parallel-group, phase 3 study, which was done in hospitals or research centres in Europe, North America, Asia, and Australia. Patients were eligible for randomisation if their sitting systolic blood pressure was 140 mm Hg or higher despite taking standardised background therapy consisting of three antihypertensive drugs, including a diuretic. The study consisted of three sequential parts: part 1 was the 4-week double-blind, randomised, and placebo-controlled part, in which patients received aprocitentan 12·5 mg, aprocitentan 25 mg, or placebo in a 1:1:1 ratio; part 2 was a 32-week single (patient)-blind part, in which all patients received aprocitentan 25 mg; and part 3 was a 12-week double-blind, randomised, and placebo-controlled withdrawal part, in which patients were re-randomised to aprocitentan 25 mg or placebo in a 1:1 ratio. The primary and key secondary endpoints were changes in unattended office systolic blood pressure from baseline to week 4 and from withdrawal baseline to week 40, respectively. Secondary endpoints included 24-h ambulatory blood pressure changes. The study is registered on ClinicalTrials.gov, NCT03541174. FINDINGS The PRECISION study was done from June 18, 2018, to April 25, 2022. 1965 individuals were screened and 730 were randomly assigned. Of these 730 patients, 704 (96%) completed part 1 of the study; of these, 613 (87%) completed part 2 and, of these, 577 (94%) completed part 3 of the study. The least square mean (SE) change in office systolic blood pressure at 4 weeks was -15·3 (SE 0·9) mm Hg for aprocitentan 12·5 mg, -15·2 (0·9) mm Hg for aprocitentan 25 mg, and -11·5 (0·9) mm Hg for placebo, for a difference versus placebo of -3·8 (1·3) mm Hg (97·5% CI -6·8 to -0·8, p=0·0042) and -3·7 (1·3) mm Hg (-6·7 to -0·8; p=0·0046), respectively. The respective difference for 24 h ambulatory systolic blood pressure was -4·2 mm Hg (95% CI -6·2 to -2·1) and -5·9 mm Hg (-7·9 to -3·8). After 4 weeks of withdrawal, office systolic blood pressure significantly increased with placebo versus aprocitentan (5·8 mm Hg, 95% CI 3·7 to 7·9, p<0·0001). The most frequent adverse event was mild-to-moderate oedema or fluid retention, occurring in 9%, 18%, and 2% for patients receiving aprocitentan 12·5 mg, 25 mg, and placebo, during the 4-week double-blind part, respectively. This event led to discontinuation in seven patients treated with aprocitentan. During the trial, a total of 11 treatment-emergent deaths occurred, none of which were regarded by the investigators to be related to study treatment. INTERPRETATION In patients with resistant hypertension, aprocitentan was well tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40. FUNDING Idorsia Pharmaceuticals and Janssen Biotech.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationStanaway, J. D., Afshin, A., Gakidou, E., Lim, S. S., Abate, D., Abate, K. H., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32225-6 · Cited by 4,943
Zhou, B., Carrillo-Larco, R. M., Danaei, G., Riley, L. M., Paciorek, C. J., Stevens, G. A., Gregg, E. W., Bennett, J. E., Solomon, B., Singleton, R. K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01330-1 · Cited by 3,902
Self-citationGerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Dolan, E., Stanton, A., Thijs, L., Hinedi, K., Atkins, N., McClory, S., Hond, E. D., McCormack, P., Staessen, J. A., & O’Brien, E. (2005) · Hypertension · doi:10.1161/01.hyp.0000170138.56903.7a · Cited by 1,227
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Self-citationRahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Ramakrishnan, R., Pinho-Gomes, A.-C., Woodward, M., Adler, A., Agodoa, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00590-0 · Cited by 1,074
Self-citationIbsen, H., Olsen, M. H., Wachtell, K., Borch-Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlöf, B., Devereux, R. B., de Faire, U., Fyhrquist, F., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000154082.72286.2a · Cited by 562
The double challenge of resistant hypertension and chronic kidney disease
Rossignol, P., Massy, Z. A., Azizi, M., Bakris, G., Ritz, E., Covic, A., Goldsmith, D., Heine, G. H., Jager, K. J., Kanbay, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00418-3 · Cited by 194
Self-citation
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citation2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Self-citationHypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
Burnier, M., & Damianaki, A. (2023) · Circulation Research · doi:10.1161/circresaha.122.321762 · Cited by 400
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Metadata
- Authors
- Schlaich, M. P., Bellet, M., Weber, M. A., Danaietash, P., Bakris, G. L., Flack, J. M., Dreier, R. F., Sassi-Sayadi, M., Haskell, L. P., Narkiewicz, K., Wang, J.-G., Reid, C., Schlaich, M., Katz, I., Ajani, A., Biswas, S., Esler, M., Elder, G., Roger, S., Colquhoun, D., Mooney, J., De Backer, T., Persu, A., Chaumont, M., Krzesinski, J.-M., Vanassche, T., Girard, G., Pliamm, L., Schiffrin, E., Merali, F., Dresser, G., Vallee, M., Jolly, S., Chow, S., Wang, J., Mu, J., Yu, J., Yuan, H., Feng, Y., Zhang, X., Xie, J., Lin, L., Soucek, M., Widimsky, J., Cifkova, R., Vaclavik, J., Ullrych, M., Lukac, M., Rychlik, I., Guldager Lauridsen, T., Kantola, I., Taurio, J., Ukkola, O., Ormezzano, O., Gosse, P., Azizi, M., Courand, P.-Y., Delsart, P., Tartiere, J. M., Mahfoud, F., Schmieder, R., Stegbauer, J., Lurz, P., Koziolek, M., Ott, C., Toursarkissian, N., Tsioufis, K., Kyfnidis, K., Manolis, A., Patsilinakos, S., Zebekakis, P., Karavidas, A., Denes, P., Bezzegh, K., Zsom, M., Kovacs, L., Sharabi, Y., Elias, M., Sukholutsky, I., Yosefy, C., Kenis, I., Atar, S., Volpe, M., Maria Lorenza, M., Taddei, S., Grassi, G., Veglio, F., Son, J. W., Kim, J.-Y., Park, J.-I., Lee, C. H., Lee, H.-Y., Raugaliene, R., Marcinkeviciene, J. E., Kavaliauskiene, R., Deinum, J., Kroon, A., van den Born, B.-J., Januszewicz, A., Tykarski, A., Walczewska, J., Gaciong, Z., Wiecek, A., Chrostowska, M., Kleinrok, A., Krekora, J., Kania, G., Podrazka-Szczepaniak, A., Golawski, C., Podziewski, M., Kaczmarek, B., Skoczylas, G., Wilkolaski, A., Wozniak, I., Janik-Palazzolo, M., Rewerska, B., Konradi, A., Shvarts, Y., Pecherina, T., Nikolaev, K., Liudmila, G., Orlikova, O., Mordovin, V., Petrochenkova, N., Kamalov, G., Kosmacheva, E., Nikolaev, K., Tyrenko, V., Gorbunov, V., Obrezan, A., Supryadkina, T., Ler, I., Kotenko, O., Kuzin, A., Martínez García, F., Redon, J., Oliveras, A., Beltran Romero, L., Shatylo, V., Rudenko, L., Bazylevych, A., Rudyk, Y., Karpenko, O., Stanislavchuk, M., Tseluyko, V., Kushnir, M., Asanov, E., Sirenko, Y., Yagensky, A., Collier, D., Gupta, P., Webb, D., MacLeod, M., McLay, J., Peace, A., Arora, S., Buchanan, P., Harris, R., Degarmo, R., Guillen, M., Karns, A., Neutel, J., Paliwal, Y., Pettis, K., Toth, P. D., Wayne, J. M., Butcher, M. B., Diller, P. M., Oparil, S., Calhoun, D., Brautigam, D., Flack, J., Goldman, J. M., Rashidi, A., Aslam, N., Haley, W., Andrawis, N., Lang, B., Miller, R., Powell, J., Dewhurst, R., Pritchard, J., Khanna, D., Tang, D., Gabra, N., Park, J., Jones, C., Scott, C., Luna, B., Mussaji, M., Bhagwat, R., Bauer, M., McGinty, J., Nambiar, R., Sangrigoli, R., Davis, W. R., Eaves, W., McGrew, F., Awad, A., Bolster, E., Scott, D., Kalirao, P., Dabel, P., Calhoun, W., Gouge, S., Warren, M., Lawrence, M. K., Jamal, A., El-Shahawy, M., Mercado, C., Kumar, J., Velasquez-Mieyer, P., Busch, R., Lewis, T., & Rich, L.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 400
- Issue
- 10367
- Pages
- 1927-1937
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4308405423
- Cited by
- 248
- References
- 9
- FWCI
- 31.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02034-7
- The paper
- Schlaich, M. P., Bellet, M., Weber, M. A., Danaietash, P., Bakris, G. L., Flack, J. M., Dreier, R. F., Sassi-Sayadi, M., Haskell, L. P., Narkiewicz, K., Wang, J.-G., Reid, C., Schlaich, M., Katz, I., Ajani, A., Biswas, S., Esler, M., Elder, G., Roger, S., . . . Rich, L. (2022). Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02034-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.